Skip to main
RGNX
RGNX logo

REGENXBIO (RGNX) Stock Forecast & Price Target

REGENXBIO (RGNX) Analyst Ratings

Based on 17 analyst ratings
Buy
Strong Buy 35%
Buy 35%
Hold 24%
Sell 6%
Strong Sell 0%

Bulls say

Regenxbio Inc. has demonstrated significant progress in its gene therapy initiatives, particularly with dose level 2 showing robust microdystrophin expression and improved functional outcomes within 9 to 12 months, bolstering investor confidence in its ongoing research. The company's recent completion of the BLA submission for accelerated approval of clemidsogene lanparvovec (RGX-121) for MPS II positions it strategically for potential FDA approval in the second half of 2025, which would mark a significant milestone for both the company and the gene therapy landscape. Although Regenxbio reported a net loss of $51.2 million for the quarter, which was lower than projections, the overall revenue of $21.2 million reflects a consistent performance, highlighting the strength of its developmental pipeline and licensed programs despite external market influences.

Bears say

Regenxbio Inc. has reported declining revenues, with FY24 revenues at $83.3 million, a decrease from $90.2 million in the previous year, alongside a reduction in R&D expenses to $208.5 million from $232.3 million, suggesting potential challenges in its research initiatives. Additionally, the company's G&A expenses also fell to $76.6 million, down from $88.5 million, indicating ongoing cost management efforts. However, concerns regarding potential delays in data releases and insufficient manufacturing capacity could adversely affect sentiment and lead to downward revisions in financial forecasts, raising doubts about the company's growth prospects.

REGENXBIO (RGNX) has been analyzed by 17 analysts, with a consensus rating of Buy. 35% of analysts recommend a Strong Buy, 35% recommend Buy, 24% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of REGENXBIO and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About REGENXBIO (RGNX) Forecast

Analysts have given REGENXBIO (RGNX) a Buy based on their latest research and market trends.

According to 17 analysts, REGENXBIO (RGNX) has a Buy consensus rating as of Jul 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

REGENXBIO (RGNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.